About NORVELZO
NORVELZO® (BORTEZOMIB FOR INJECTION) 1mg / 2mg / 3.5 mg in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. - White to off-white cake or powder. NORVELZO 3.5 mg as monotherapy is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for 3.5 MG BORTEZOMIB (as a mannitol boronic ester). NORVELZO 3.5 mg in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

About Taj Pharma Group
Taj Pharma is one of the leading generic and branded pharmaceutical manufacturing company in India. We hold top positions in different established markets worldwide and are building a strong presence in many emerging generics markets. We have eight manufacturing sites in India to support our market standing, holding a strong regulatory position and major certifications for most markets. Today, we market more than 500 branded and 4600 generics compositions to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.